{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-23-000096","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.708944+00:00","generated_at":"2026-06-08T15:28:47.806005+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Summit Therapeutics Q3 net loss $21.3M; starts second Phase III for ivonescimab","bullets":["Net loss Q3 $21.3M; nine-month 2023 net loss $578.4M includes $520.9M one-time IPR&D charge from ivonescimab licensing.","Cash, equivalents, and short-term investments $198.9M at Sep 30, 2023 (down from $648.6M Dec 2022); $100M notes payable due Sep 2024; expects funds into H2 2024.","Enrollment initiated in HARMONi-3 Phase III trial for ivonescimab in first-line metastatic squamous NSCLC; HARMONi enrollment completion expected H2 2024.","Manmeet S. Soni appointed COO and invested $5M; multiple internal promotions and hiring of Dr. Jack West and Dr. Laura Chow in clinical development."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-23-000096","json":"https://secwatch.observer/filing/0001599298-23-000096.json","markdown":"https://secwatch.observer/filing/0001599298-23-000096.md","text":"https://secwatch.observer/filing/0001599298-23-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/0001599298-23-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/smmt-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:28:47.806005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9770df9609a549dba2f26b7171bb2529e21d055","claim":"Summit Therapeutics Inc. reported financial results for the third quarter and nine months ended September 30, 2023.","evidence_excerpt":"Summit Therapeutics Inc. (NASDAQ: SMMT) (\"Summit,\" \"we,\" or the \"Company\") today reports its financial results and provides an update on operational progress for the third quarter and nine months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/0001599298-23-000096-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}